Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

Published:2018-01 Issue:1 Volume:12 Page:173-184
ISSN:1933-2874
Container-title:Journal of Clinical Lipidology
language:en
Short-container-title:Journal of Clinical Lipidology

Author:

Ishibashi Shun^ORCID,Arai Hidenori,Yokote Koutaro,Araki Eiichi,Suganami Hideki,Yamashita Shizuya

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference46 articles.

1. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials;Cholesterol Treatment Trialists C;Lancet,2015

2. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia;Fruchart;Am J Cardiol,2008

3. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology;Nordestgaard;Circ Res,2016

4. Use of fibrates in the metabolic syndrome: a review;Shipman;World J Diabetes,2016

5. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1–full report;Jacobson;J Clin Lipidol,2015

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of PPAR Ligands and Nanoparticle Technology in Metabolic Steatohepatitis Treatment;Biomedicines;2024-08-16

2. Iron‐Promoted Redox Access to 2‐Aminobenzoxazoles from Amines, Carbon Disulfide and 2‐Nitrophenols;Asian Journal of Organic Chemistry;2024-08-14

3. Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease;Hormones;2024-08-07

4. Drug–drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open‐label, randomized, 6‐sequence, 3‐period crossover studies;Clinical and Translational Science;2024-07-30

5. Switching from Conventional Fibrates to Pemafibrate Has Beneficial Effects on the Renal Function of Diabetic Subjects with Chronic Kidney Disease;Diabetes & Metabolism Journal;2024-05-31